Back to Feed
总结
在摩根大通年度医疗健康大会（JPM）于旧金山举行前夕，制药与生物科技公司管理层、投资机构和并购顾问集中到场路演与会谈。报道关注市场将从企业指引、研发管线与资本开支表态中判断行业景气度，以及融资环境是否改善、并购活动是否在2026年进一步升温并出现更大规模交易。同时，药价与监管不确定性仍被视为影响企业估值与交易节奏的关键变量。
正文
Healthy Returns: What to expect from pharma at the JPM conference CNBC Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 Yahoo Finance JPM to bring more deals and happy CEOs statnews.com Will biotech's big JPM conference signal a new normal for the industry and San Francisco? The Business Journals JPM 2026: What to know about the San Francisco conference Modern Healthcare News
发布时间：